ACE2 and obesity disorder: In addition to the protection reported to be provided by spironolactone, specific actions against SARS-CoV-2 actions have been proposed, including increased availability of free circulating ACE2 in response to a hyperreninemic state induced by MR antagonism [98–104], reduction of TMPRSS2 expression due to antagonism of AR [105–107], reversal of RAAS abnormalities induced by obesity [108, 109], and possible direct anti-inflammatory and anti-viral actions that hamper lung injuries [110–121].